Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective (Q29339): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Created a new Item) |
Superraptor (talk | contribs) (Added [en] label: Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective) |
||
| label / en | label / en | ||
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective | |||
Revision as of 21:52, 6 November 2024
No description defined
- Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective |
No description defined |
|
Statements
Gender incongruence and the number of people seeking gender affirming hormone treatment has dramatically risen in the last two decades. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
In the UK, transgender women and non-binary transfeminine individuals are typically treated with simultaneous suppression of endogenous testosterone production through anti-androgens and exogenous oestradiol replacement. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
Oestrogen replacement comes in different forms and is primarily given as transdermal (gel or patch) or oral preparations in the UK. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
Decisions around preparation choice are based on a combination of individual preference and/or mitigating the chance of complications based on individual risk profiles. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
Time frames to achieve female physical changes are largely predictable and managing expectations of individuals prior to commencing treatment is highly important. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
Common complications include venous thromboembolism, liver dysfunction and effects on fertility, thus individuals should be thoroughly counselled prior to commencing treatment. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
This article provides an overview of the management and considerations of gender-affirming hormone treatment in transgender women and non-binary transfeminine individuals. (English)
Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved. (English)
2024
Rebecca C (English)
Sagar (English)
RC
Victoria (English)
Millson-Brown (English)
V
13 September 2024
13 September 2024